Diplomat Pharmacy Inc (NYSE:DPLO) shares dropped 5.5% on Thursday . The company traded as low as $17.80 and last traded at $18.06. Approximately 651,878 shares changed hands during trading, a decline of 33% from the average daily volume of 974,667 shares. The stock had previously closed at $19.11.
DPLO has been the topic of a number of analyst reports. ValuEngine upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Saturday, June 16th. Leerink Swann reiterated an “outperform” rating and set a $33.00 price objective on shares of Diplomat Pharmacy in a research report on Friday, June 22nd. Finally, Morgan Stanley boosted their price objective on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 3rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. Diplomat Pharmacy presently has a consensus rating of “Hold” and an average target price of $26.90.
The company has a current ratio of 0.91, a quick ratio of 0.63 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $1.44 billion, a P/E ratio of 21.80 and a beta of 1.13.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, August 6th. The company reported $0.17 EPS for the quarter, missing the Zacks’ consensus estimate of $0.23 by ($0.06). The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.42 billion. Diplomat Pharmacy had a return on equity of 7.86% and a net margin of 0.06%. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.25 earnings per share. As a group, equities analysts forecast that Diplomat Pharmacy Inc will post 0.83 EPS for the current fiscal year.
In other news, Director Philip R. Hagerman sold 209,367 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $19.07, for a total value of $3,992,628.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Philip R. Hagerman sold 57,500 shares of the company’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total transaction of $1,104,575.00. The disclosure for this sale can be found here. Corporate insiders own 24.70% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in DPLO. FMR LLC lifted its stake in Diplomat Pharmacy by 154.4% in the second quarter. FMR LLC now owns 2,798,440 shares of the company’s stock worth $71,528,000 after acquiring an additional 1,698,341 shares during the period. Janus Henderson Group PLC lifted its stake in Diplomat Pharmacy by 30.7% in the second quarter. Janus Henderson Group PLC now owns 5,385,168 shares of the company’s stock worth $137,645,000 after acquiring an additional 1,265,271 shares during the period. Victory Capital Management Inc. lifted its stake in Diplomat Pharmacy by 17,568.5% in the second quarter. Victory Capital Management Inc. now owns 1,239,442 shares of the company’s stock worth $31,679,000 after acquiring an additional 1,232,427 shares during the period. Point72 Asset Management L.P. lifted its stake in Diplomat Pharmacy by 1,424.3% in the first quarter. Point72 Asset Management L.P. now owns 939,562 shares of the company’s stock worth $18,932,000 after acquiring an additional 877,922 shares during the period. Finally, Redwood Investments LLC purchased a new stake in Diplomat Pharmacy in the first quarter worth about $16,716,000. 80.89% of the stock is owned by institutional investors.
About Diplomat Pharmacy (NYSE:DPLO)
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.